Turello Lara A, Consul Amber, Yip Christopher, Shen Shirley, Seymour Cale, Geurink Corey, Alvarado Israel, Abel-Santos Ernesto
Department of Chemistry and Biochemistry, University of Nevada, Las Vegas, Las Vegas, NV, USA.
Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, Las Vegas, NV, 89154-4004, USA.
J Antibiot (Tokyo). 2025 Jan;78(2):113-125. doi: 10.1038/s41429-024-00795-3. Epub 2024 Dec 13.
Clostridioides difficile infection (CDI) is the most common nosocomial infection in the US. CDI has become a growing concern due to C. difficile's resistance to several antibiotics, including cephalosporins. Furthermore, patients administered cephalosporins are at higher risk of contracting CDI. Cephalosporins are β-lactam antibiotics, which prevent bacterial cell wall synthesis by inhibiting penicillin-binding proteins (PBPs). β-lactam-resistant bacteria evade these antibiotics by producing β-lactamases or by harboring low-affinity PBPs. A genomic analysis of C. difficile strain 630 identified 31 putative β-lactam resistance genes. Upon cefoxitin exposure, few C. difficile strain 630 putative antibiotic-resistant genes were overexpressed. Most notably, the β-lactamase blaCDD gene was upregulated approximately 600-fold, as previously reported. Deletion of the blaCDD locus did not change in cephalosporin susceptibility. Deletion of the second most upregulated gene, the PBP vanY, was also ineffective at decreasing cephalosporin resistance. Cefoxitin exposure of the C. difficile strain 630ΔblaCDD mutant did not increase upregulation of other putative antibiotic resistance genes compared to wildtype C. difficile strain 630. Transcriptomic analyses of wildtype C. difficile strain 630 exposed to cephradine, cefoxitin, ceftazidime, or cefepime revealed the shared upregulation of a putative heterodimeric ABC transporter encoded by loci CD630_04590 (ABC transporter ATP-binding protein) and CD630_04600 (ABC transporter permease). These genes are genomically located directly downstream of blaCDD (CD630_04580). The deletion mutant CD630_04600 remained resistant to a number of antibiotics. Thus, even though blaCDD, CD630_04590, and CD630_04600 are all upregulated when exposed to cephalosporins, they do not seem to be involved in antibiotic resistance in C. difficile strain 630.
艰难梭菌感染(CDI)是美国最常见的医院感染。由于艰难梭菌对包括头孢菌素在内的多种抗生素具有耐药性,CDI已成为一个日益受到关注的问题。此外,使用头孢菌素的患者感染CDI的风险更高。头孢菌素是β-内酰胺类抗生素,通过抑制青霉素结合蛋白(PBPs)来阻止细菌细胞壁的合成。耐β-内酰胺类细菌通过产生β-内酰胺酶或携带低亲和力的PBPs来逃避这些抗生素。对艰难梭菌630菌株的基因组分析确定了31个假定的β-内酰胺耐药基因。在头孢西丁暴露后,艰难梭菌630菌株的少数假定抗生素耐药基因被过度表达。最值得注意的是,β-内酰胺酶blaCDD基因上调了约600倍,如先前报道。blaCDD基因座的缺失并未改变对头孢菌素的敏感性。第二上调基因PBP vanY的缺失在降低头孢菌素耐药性方面也无效。与野生型艰难梭菌630菌株相比,艰难梭菌630ΔblaCDD突变体在头孢西丁暴露下并未增加其他假定抗生素耐药基因的上调。对暴露于头孢拉定、头孢西丁、头孢他啶或头孢吡肟的野生型艰难梭菌630菌株的转录组分析显示,由基因座CD630_04590(ABC转运蛋白ATP结合蛋白)和CD630_04600(ABC转运蛋白通透酶)编码的假定异源二聚体ABC转运蛋白共同上调。这些基因在基因组上直接位于blaCDD(CD630_04580)的下游。缺失突变体CD630_04600对多种抗生素仍具有耐药性。因此,尽管blaCDD、CD630_04590和CDI630_04600在暴露于头孢菌素时均上调,但它们似乎与艰难梭菌630菌株的抗生素耐药性无关。